SAN DIEGO, May 6, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) is dedicated to providing first-in-class medicines. A clinical-stage biopharmaceutical company. The pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for patients with cancer and autoimmune diseases will be announced via conference call and audio webcast on Thursday, May 9, 2024 at 5:00 p.m. ET. We will be hosting a live broadcast to present our first quarter 2024 financial results and operational updates, including a review of our FT819 and FT522 programs for autoimmune diseases, to be featured on the same day at the American Society for Gene and Cell Therapy meeting. Highlight information27th Annual meeting.
To join the conference call, dial (833) 630-1956 (domestic) and (412) 317-1837 (international). The live webcast can be accessed under “Events and Presentations” in the Investor section of our website (www.fatetherapeutics.com). The archived webcast will be available on our website approximately two hours after the event.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the company has established a leadership position in the creation of multiplexed engineered master iPSC lines as well as the manufacturing and clinical development of off-the-shelf iPSC-derived cell products. The company's pipeline includes iPSC-derived natural killer (NK) cell and T cell product candidates that are selectively engineered, incorporate novel synthetic controls on cellular function, and have multiple therapeutic mechanisms. It is intended to be provided to patients. Fate Therapeutics is headquartered in San Diego, California. For more information, please visit www.fatetherapeutics.com.
contact:
Christina Tartaglia
Stern Investor Relations Co., Ltd.
212-362-1200
christina.tartaglia@sternir.com
